10x Genomics (TXG) Equity Average (2019 - 2025)
Historic Equity Average for 10x Genomics (TXG) over the last 7 years, with Q4 2025 value amounting to $790.7 million.
- 10x Genomics' Equity Average rose 1036.39% to $790.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $790.7 million, marking a year-over-year increase of 1036.39%. This contributed to the annual value of $753.2 million for FY2025, which is 380.95% up from last year.
- As of Q4 2025, 10x Genomics' Equity Average stood at $790.7 million, which was up 1036.39% from $779.2 million recorded in Q3 2025.
- 10x Genomics' 5-year Equity Average high stood at $812.1 million for Q1 2022, and its period low was $708.5 million during Q1 2025.
- Moreover, its 5-year median value for Equity Average was $774.2 million (2023), whereas its average is $765.9 million.
- In the last 5 years, 10x Genomics' Equity Average skyrocketed by 9204.98% in 2021 and then plummeted by 957.54% in 2024.
- Over the past 5 years, 10x Genomics' Equity Average (Quarter) stood at $808.9 million in 2021, then dropped by 2.24% to $790.8 million in 2022, then fell by 6.02% to $743.1 million in 2023, then decreased by 3.59% to $716.5 million in 2024, then grew by 10.36% to $790.7 million in 2025.
- Its Equity Average stands at $790.7 million for Q4 2025, versus $779.2 million for Q3 2025 and $740.1 million for Q2 2025.